Clinical Trial Update: Pilot Study of PLX3397 in Patients With Advanced Castration-Resistant Prostate Cancer (CRPC) [Phase 2]

View source ↗

Summary

Phase 2 pilot study of PLX3397 in advanced castration-resistant prostate cancer was terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• PLX3397 (PLX3397)

Snippet

Sponsor: Daiichi Sankyo | Conditions: Prostate Cancer | Phase 2 | Status: TERMINATED | Results posted: 2019-10-18